Background: TR-700, the active component of the oxazolidinone prodrug TR-701, has demonstrated potent activity against numerous Gram-positive species. In this study, single-step mutation frequencies, passaging and the activity of TR-700 were tested against a worldwide collection of linezolidnon-susceptible organisms and matched controls.
Introduction
Linezolid, the first approved antibacterial agent of the oxazolidinone class, has become an important agent for the treatment of serious infections caused by Gram-positive cocci. 1 Strains having a linezolid MIC of 4 mg/L (staphylococci) or 2 mg/L (streptococci and enterococci) are susceptible to linezolid, as defined by the United States Food and Drug Administration and the CLSI (formerly NCCLS). Since its regulatory approval in 2000, several species of Gram-positive pathogens have been identified with elevated MIC values (!8 mg/L) for linezolid. 2, 3 The mechanisms of linezolid resistance have generally been determined and found to be dominated by 23S rRNA target mutations, usually at one of four sites (G2576T, T2500A, G2505A, G2447T), some only occurring in laboratory-derived strains. 3 More recently, resistance due to a transferable rRNA methyltransferase gene, named cfr, has been described in veterinary and human isolates of staphylococci. 4 Oxazolidinone agents are considered bacteriostatic and clinical utility has been determined by pharmacokinetic/pharmacodynamic (PK/PD) parameters balanced against a predictable toxicity profile. Therefore, advances in this class will require greater potencies against linezolid-non-susceptible Gram-positive pathogens [including Staphylococcus aureus, coagulase-negative staphylococci (CoNS) and Enterococcus faecium or Enterococcus faecalis], improved PK/PD target attainment and greater safety.
This study determined the potency and spectrum of activity of a new oxazolidinone, TR-700, the active moiety of the prodrug TR-701 5, 6 against a collection of linezolid-non-susceptible isolates having well-characterized resistance mechanisms, including four clinical isolates of cfr-carrying staphylococcal. Comparator agents were concurrently tested as well as geographically matched control strains (linezolid-susceptible). Additionally, multipassage resistance selection and frequency of spontaneous single-step mutation studies were performed.
Materials and methods

Bacterial strains
A total of 120 linezolid non-susceptible clinical strains, as determined by CLSI M100-S18 7 breakpoint criteria, were utilized in this study. These strains had been characterized by molecular methods 2 to determine the mechanism of resistance: E. faecalis (15; all G2576T mutants), E. faecium (54; all G2576T mutants), S. aureus (8; 6 G2576T mutants and 2 carrying cfr), Staphylococcus epidermidis (24; 22 G2576T mutants and 2 carrying cfr), Staphylococcus capitis (2 G2576T mutants), Staphylococcus haemolyticus (5 G2576T mutants), Staphylococcus simulans (2 G2576T mutants), Staphylococcus xylosus (2; both G2576T mutants) and Streptococcus oralis (1 G2576T mutant). Linezolid non-susceptible strains without detectable mechanisms (seven total; mechanism under continued study) were also tested: E. faecalis (one), E. faecium (one) and S. epidermidis (five). In addition, matched linezolid-susceptible control strains (120 in total) were used to compare oxazolidinone potencies. These strains were matched by species or by genus for CoNS isolates when the same species was not available, time (same year of isolation) and institution, site of infection and clinical service.
Susceptibility testing
TR-700 (Trius Therapeutics, San Diego, CA, USA) and linezolid MIC values were compared with 12 other agents including vancomycin and daptomycin by the CLSI M7-A7 8 broth microdilution method using cation-adjusted Mueller-Hinton broth. Additional medium supplements to 50 mg/L calcium for testing daptomycin and lysed horse blood (2% to 5%) were used for testing fastidious streptococci. A disc diffusion method with oxacillin and cefoxitin discs was used to confirm methicillin resistance patterns among the staphylococci. CLSI M100-S18 7 interpretive criteria and quality control ranges of comparison agents were applied.
Passaging and single-step mutation experiments
Resistance selection studies used the entire contents of the last MIC panel well with growth to inoculate broth media. Tubes were placed in an ambient air incubator to allow growth to reach a turbidity equivalent to that of a 0.5 McFarland standard (1.5 -3 h). MIC panels were then inoculated using the appropriate volume and concentration and repeated through 14 passaging days. The strains demonstrating emerging resistance were tested against selected antimicrobial agents from other classes upon completion of passaging in order to evaluate the emergence of cross-resistance. Reversion to susceptibility was also assessed by three passages performed on drug-free media with final retesting by the broth microdilution method.
8 Eight linezolid-susceptible isolates were tested for resistance selection including two methicillin-susceptible S. aureus (MSSA) strains (ATCC 29213 and one clinical isolate), three methicillin-resistant S. aureus strains (representatives of the clones USA100, USA300 and USA400), two E. faecalis (ATCC 29212 and VanA phenotype clinical strain) and one Streptococcus pyogenes clinical isolate carrying erm(A).
The frequency of spontaneous single-step mutation was determined for S. aureus ATCC 29213, S. aureus USA300-01114 and E. faecalis ATCC 29212 against TR-700. Fresh colonies from an agar plate were emulsified in sterile broth or saline until a suspension with a turbidity equal to at least a 4 McFarland standard (!1Â10 9 cfu/mL) was achieved. The inoculum suspension (1 mL) was plated on appropriate agar plates containing 4Â, 8Â and 16Â the TR-700 MIC. Serial dilutions of the bacterial suspension were plated on antimicrobial-free agar plates to determine the colony count (cfu/mL). Table 1 summarizes the MIC results for TR-700 and comparator agents tested against 69 enterococcal and 39 staphylococcal isolates having a G2576T mutation of the 23S rRNA target. The highest MIC values were .32 mg/L for TR-700 and linezolid. TR-700 was 4-8-fold more potent, inhibiting 88.4% of Enterococcus spp. strains at 4 mg/L. The cfr-positive strains [four isolates; S. aureus (two) and S. epidermidis (two)] showed linezolid MIC values ranging from 8 to .32 mg/L, and TR-700 results were generally several fold lower (MIC range, 0.5-8 mg/L). Seven strains having linezolid MIC results reproducibly at !8 mg/L, but without a detectable resistance mechanism, are also displayed in Table 1 . TR-700 was 16-fold more active than linezolid against those strains. Only two viridans group streptococcal species [Streptococcus mitis (susceptible control) and S. oralis] were tested. The S. oralis isolate was non-susceptible to linezolid, and TR-700 was again 4-fold more potent than linezolid (data not shown). Table 2 compares the TR-700 activity with that of vancomycin against all 240 strains. When tested against linezolid-susceptible organism subsets, TR-700 was generally more active than vancomycin; however, against some linezolid-non-susceptible strains, vancomycin remained more effective in vitro, e.g. CoNS and viridans group streptococci.
Results and discussion
TR-700 MIC distributions for two organism groups showed that the median MIC values markedly favoured TR-700 (Table 3) . Only one enterococcus and 13 staphylococci among 120 strains (11.7%) would be considered TR-700-non-susceptible, if the same susceptibility breakpoints used for linezolid were applied to this investigational oxazolidinone.
TR-700 results among the compared (TR-700 versus linezolid) strains showed no passaging series MIC increases. In contrast, the three tested strains exhibited a 2-fold increase in the linezolid MIC (data not shown). The tests with the non-compared strains indicated a consistent 2-fold TR-700 MIC elevation for three organisms (MSSA clinical isolate, VanA phenotype E. faecalis, erm(A)-carrying S. pyogenes) and no change in the TR-700 MIC for the remaining strains. Strains with elevated MIC values at the end of the experiment (all remained in susceptible MIC ranges 4 mg/L for linezolid; but 0.5 mg/L for TR-700) had MIC values that returned to baseline. 
TR-700 versus Gram-positive pathogens
SQ1
Single-step mutation experiments showed that for the two S. aureus isolates (ATCC 29213 and USA300-0114) and the E. faecalis ATCC 29212, no growth was observed in plates of 4Â, 6Â and 8Â the MIC with inocula of 2.2Â10 9 cfu/mL for both S. aureus isolates and 1.1Â10 9 cfu/mL for the E. faecalis isolate. In conclusion, reference CLSI broth microdilution methods 8 were used to evaluate TR-700, when tested against linezolidrefractory Gram-positive cocci (120 isolates), and an equal number of matched wild-type strains. TR-700 was noted to be 4-32-fold more active than linezolid, but the observed potency could vary by species and documented resistance mechanisms. Many (nearly 90%) linezolid-non-susceptible isolates had TR-700 MIC results at 4 mg/L. Furthermore, the occurrence of MIC elevations after 14 passage days for TR-700 was less than linezolid in direct comparison experiments, and single-step mutational rates for TR-700 were extremely low. Clearly, continued investigation of this novel oxazolidinone is warranted to establish its role against multidrug-resistant Gram-positive pathogens. Table 2 ).
